{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:22Z","timestamp":1786979902780,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-mediated myocarditis results in significant morbidity and mortality. At our institution, we noted an increased incidence of ICI-mediated myocarditis cases, leading to further investigation in our database of advanced melanoma patients treated with ICI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective cohort analysis of patients with advanced melanoma identified cases of ICI-mediated myocarditis and myositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>366 patients with advanced melanoma received a dose of ICI from September 2014 to October 2019. Of these patients, there were 0 cases of ICI-mediated myocarditis (0%, 95% CI 0%\u20131.0%) and 2 cases of ICI-mediated myositis (0.55%, 95% CI 0.07%\u20131.96%). From November 2019 to December 2021, an additional 246 patients with advanced melanoma were identified. Of these patients, 10 (4.1%, 95% CI 1.97%\u20137.35%) developed ICI-mediated myocarditis and 10 developed ICI-mediated myositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study suggests an increase in prevalence of ICI-mediated muscle damage including myositis and myocarditis in the COVID-19 era. Differentiation of these patients and further risk stratification may allow for development of guidelines for nuanced management of this serious complication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-024-03803-5","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T12:01:47Z","timestamp":1728129707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era"],"prefix":"10.1007","volume":"73","author":[{"given":"Allison L.","family":"Gradone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi","family":"Vasbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Yentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"16","key":"3803_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, M\u00e1rquez-Rodas I, Haanen J, Guidoboni M, Maio M, Sch\u00f6ffski P, Carlino MS, Lebb\u00e9 C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"issue":"26","key":"3803_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) KEYNOTE-006 investigators. pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"12","key":"3803_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"5","key":"3803_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A et al (2022) Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC Cardio Oncol 4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004","journal-title":"JACC Cardio Oncol"},{"issue":"12","key":"3803_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"issue":"10124","key":"3803_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"key":"3803_CR7","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","volume":"11","author":"T Makunts","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV et al (2021) Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 11:17324. https:\/\/doi.org\/10.1038\/s41598-021-96467-5","journal-title":"Sci Rep"},{"issue":"2","key":"3803_CR8","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9(2):e013757. https:\/\/doi.org\/10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"issue":"36","key":"3803_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"2","key":"3803_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140(2):80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"issue":"10145","key":"3803_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","volume":"392","author":"SG Al-Kindi","year":"2018","unstructured":"Al-Kindi SG, Oliveira GH (2018) Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 392(10145):382\u2013383. https:\/\/doi.org\/10.1016\/S0140-6736(18)31542-3","journal-title":"Lancet"},{"issue":"24","key":"3803_CR12","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.121.058489","volume":"145","author":"J de Du Fay Lavallaz","year":"2022","unstructured":"de Du Fay Lavallaz J, Prepoudis A, Wendebourg MJ et al (2022) Skeletal muscle disorders: a noncardiac source of cardiac troponin T. Circulation 145(24):1764\u20131779. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058489","journal-title":"Circulation"},{"key":"3803_CR13","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.02.0","author":"G Lie","year":"2020","unstructured":"Lie G, Weickhardt A, Kearney L et al (2020) Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma case report. Trans Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr.2020.02.0","journal-title":"Trans Lung Cancer Res"},{"issue":"23","key":"3803_CR14","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1161\/CIRCULATIONAHA.120.047164","volume":"141","author":"JA Fried","year":"2020","unstructured":"Fried JA, Ramasubbu K, Bhatt R et al (2020) The variety of cardiovascular presentations of COVID-19. Circulation 141(23):1930\u20131936. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047164","journal-title":"Circulation"},{"issue":"23","key":"3803_CR15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","volume":"385","author":"G Witberg","year":"2021","unstructured":"Witberg G, Barda N, Hoss S et al (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa2110737","journal-title":"N Engl J Med"},{"issue":"12","key":"3803_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385(12):1078\u20131090. https:\/\/doi.org\/10.1056\/NEJMoa2110475","journal-title":"N Engl J Med"},{"key":"3803_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15585\/mmwr.mm7035e5external","volume":"70","author":"TK Boehmer","year":"2021","unstructured":"Boehmer TK, Kompaniyets L, Lavery AM et al (2021) Association between COVID-19 and myocarditis using hospital-based administrative data\u2014United States march 2020\u2013january 2021. MMWR Morb Mortal Wkly Rep 70:1228\u20131232. https:\/\/doi.org\/10.15585\/mmwr.mm7035e5external","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"3803_CR18","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jamacardio.2021.2065","volume":"6","author":"CJ Daniels","year":"2021","unstructured":"Daniels CJ, Rajpal S, Greenshields JT et al (2021) Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol 6(9):1078\u20131087. https:\/\/doi.org\/10.1001\/jamacardio.2021.2065","journal-title":"JAMA Cardiol"},{"issue":"1","key":"3803_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cardiores.2007.03.012","volume":"75","author":"Y Seko","year":"2007","unstructured":"Seko Y, Yagita H, Okumura K, Azuma M, Nagai R (2007) Roles of programmed death-1 (PD-1)\/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovasc Res 75(1):158\u2013167. https:\/\/doi.org\/10.1016\/j.cardiores.2007.03.012","journal-title":"Cardiovasc Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03803-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T07:05:04Z","timestamp":1731740704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03803-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3803"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03803-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VTM serves as a consulting or advisory role for Immunocore, Regeneron, Bristol Myers Squibb, Incyte, Replimune, and Partner Therapeutics. CL receives clinical trial funding from BMS, Novartis and\u00a0is currently\u00a0employed by BMS. LF receives clinical trial funding from BMS, Kartos, Array\/Pfizer, Merck, Pfizer\/EMD Serono and serves as a consultant for Elsevier. AG, AV, SY, SH have no conflicts of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study protocol (HUM00156014) is approved by the University of Michigan institutional ethical guidelines and complies with the guidelines of the responsible governmental agency. Informed consent was not obtained from the subjects as it is not applicable for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"259"}}